Liposomal irinotecan combo for first-line small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of drugs (liposomal irinotecan plus others) as a first treatment for people with extensive-stage small cell lung cancer. It may offer a new approach if you haven't had any therapy yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer (spread beyond one lung).
- You have not had any previous cancer treatment for this disease.
- You are at least 18 years old and in fairly good health (able to care for yourself).
- You have at least one tumor that can be measured on a scan.
- Your blood counts and liver/kidney function are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
This trial tests a combination of two drugs (adebelizumab and irinotecan liposome) for people with advanced small cell lung cancer that got worse after first-line treatment. It aims to see if this combination works better and to find out which patients benefit the most.
This trial tests a combination of a liposome-encased chemotherapy (irinotecan), a platinum drug, an immunotherapy, and a targeted therapy (anlotinib) as a maintenance treatment for extensive small cell lung cancer. The goal is to see if this approach helps keep the cancer from growing after initial successful treatment.
This study tests a combination of an oral targeted therapy (anlotinib) with a liposomal form of chemotherapy and an immunotherapy drug as maintenance treatment for extensive-stage small cell lung cancer after initial treatment. It aims to keep the cancer from growing again.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of irinotecan liposome (a chemotherapy) or etoposide with adebrelimab (an immunotherapy) and carboplatin for people with extensive-stage small cell lung cancer who haven't had prior treatment. It aims to see if these combinations are safe and effective.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.